SleepWell Trade

Trend-Following Backtester · Guide · backtest 한국어

equity · US

CytomX Therapeutics, Inc. backtest

10 trend-following strategies were compared on the full daily history of CytomX Therapeutics, Inc.. 10 beat buy-and-hold CAGR; Supertrend ranks first by Sharpe, matching the main backtester.

Data 2015-10-08 ~ 2026-07-31daily bars 2,718 (10.8 years)Costs 0.5%Venue XNASMonthly snapshot 2026-07-31

Results by strategy

10 of 10 beat buy and hold (CAGR -12.4%, drawdown -98.7%).

Sharpe leader (same as main): Supertrend — CAGR 16.6%, MDD -83.1%, Sharpe 0.52, 37% exposure.

No strategy retained at least 75% of buy-and-hold CAGR while reducing drawdown by both 20% relatively and 5 percentage points absolutely.

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
Supertrend
period=11, mult=3.2
16.6%-83.1%0.520.205.3x4537%
ADX / DI 방향성
period=11, threshold=30
6.1%-85.2%0.330.071.9x6018%
Donchian 채널 돌파
entryN=65, exitN=72
0.1%-92.0%0.320.001.0x1846%
SMA 크로스오버
fast=9, slow=142
-0.4%-90.5%0.30-0.001.0x3236%
MACD
fast=22, slow=28, signal=18
-0.7%-93.6%0.29-0.010.9x10852%
Keltner 채널 돌파
emaPeriod=48, atrPeriod=20, mult=1.5
0.7%-84.6%0.280.011.1x5228%
볼린저 밴드 돌파
n=63, k=0.9
-1.5%-89.3%0.25-0.020.9x5831%
ROC 모멘텀
n=51, threshold=-0.03
-7.5%-93.2%0.24-0.080.4x15646%
Parabolic SAR
step=0.005, maxStep=0.12
-4.6%-96.7%0.22-0.050.6x8040%
EMA 크로스오버
fast=26, slow=91
-9.3%-90.0%0.17-0.100.3x3234%
Buy and hold-12.4%-98.7%0.29-0.130.2x1100%
0.1 1x 2016 2018 2020 2022 2024 2026 SupertrendBuy and hold
Supertrend: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -25% -49% -74% -99% 2016 2018 2020 2022 2024 2026 Buy and holdSupertrend
Supertrend maximum drawdown -83.1% (2020-05-12 → 2025-04-16), recovered after 2,075 days.

Rules of the top strategy

Trades the direction of a volatility-based trend line that trails below/above price.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupMore US assetsAll asset reports

Read next